Loading...
•
Dec 31, 2024
Stryker Q4 2024 Earnings Report
Stryker's Q4 2024 results showed strong organic sales growth and adjusted EPS, but were impacted by goodwill and other impairments related to the Spine business.
Key Takeaways
Stryker reported a 10.7% increase in net sales to $6.4 billion, with organic net sales up 10.2%. Adjusted EPS increased by 15.9% to $4.01, while reported EPS decreased 52.7% to $1.41 due to non-cash charges for goodwill and other impairments. The company anticipates organic net sales growth of 8.0% to 9.0% for 2025 and adjusted net earnings per diluted share to be in the range of $13.45 to $13.70.
Net sales increased by 10.7% to $6.4 billion.
Organic net sales increased by 10.2%.
Adjusted EPS increased by 15.9% to $4.01.
Reported EPS decreased 52.7% to $1.41, impacted by goodwill and other impairments.
Stryker
Stryker
Forward Guidance
Stryker anticipates organic net sales growth of 8.0% to 9.0% for 2025 and adjusted net earnings per diluted share to be in the range of $13.45 to $13.70.
Positive Outlook
- Momentum exiting 2024
- Sustained level of procedural volumes
- Strong demand for capital products
- Presence in healthy end markets
- Full year impact of price on sales will be modestly favorable
Challenges Ahead
- Full year net sales will be unfavorably impacted by approximately 1% due to foreign exchange rates
- Adjusted net earnings per diluted share will be negatively impacted by approximately $0.10 to $0.15 due to foreign exchange rates
- Inari is expected to deliver approximately $590 million of sales in the 2025 stub period on a constant currency basis
- Inari will have dilutive impacts on adjusted operating income margin of 0 to 20 basis points
- Inari will have dilutive impacts on adjusted net earnings per diluted share of $0.20 to $0.30